<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00796822</url>
  </required_header>
  <id_info>
    <org_study_id>614</org_study_id>
    <secondary_id>R01HL095149</secondary_id>
    <nct_id>NCT00796822</nct_id>
  </id_info>
  <brief_title>Evaluating the Effectiveness of Pentoxifylline at Improving Blood Vessel Function in HIV-infected People Not Receiving Antiretroviral Medications</brief_title>
  <official_title>A Randomized, Placebo-Controlled Trial of Pentoxifylline to Improve Endothelial Function in HIV-Infected Patients Not Requiring Antiretroviral Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indiana University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      People infected with HIV have a greater risk of developing cardiovascular disease than people
      not infected with HIV. This may be due to increased inflammation brought on by either the HIV
      infection itself or the use of antiretroviral medications to treat HIV infection. This study
      will evaluate an anti-inflammatory drug, pentoxifylline, to determine whether it improves
      blood vessel function and reduces inflammation in people infected with HIV who are not
      currently receiving antiretroviral medications.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      People infected with HIV have an increased risk for cardiovascular disease, which is a
      leading cause of death for those with HIV. The increase in cardiovascular disease has been
      thought to be linked to the use of several types of antiretroviral medications used to treat
      HIV infection. These medications have been shown to cause insulin resistance and
      dyslipidemia, or high cholesterol levels—conditions that can lead to atherosclerosis, which
      is a build-up of plaque within the arteries, and ultimately to cardiovascular disease.
      However, new research is emerging that suggests that people infected with HIV who do not
      receive antiretroviral medications may also have an increased risk of cardiovascular disease
      as a result of increased endothelial dysfunction. This condition, which involves
      malfunctioning of the thin layer of cells that line the interior surface of blood vessels,
      can lead to atherosclerosis and cardiovascular disease. Pentoxifylline is a medication that
      is currently used to reduce leg pain in people with blockages in the blood vessels in their
      legs. Previous research has shown that pentoxifylline may reduce inflammation and improve
      blood vessel function in people infected with HIV, but more research is needed to confirm
      these benefits. The purpose of this study is to determine whether pentoxifylline reduces
      inflammation and improves endothelial function in HIV-infected people who are not receiving
      antiretroviral medications.

      This study will enroll HIV-infected people who are not currently receiving antiretroviral
      medications. At a baseline study visit, participants will undergo a medical history review;
      physical examination; measurements in blood pressure, heart rate, height, weight, waist, and
      hip; and blood and urine collection. An ultrasound imaging test of the arm will measure blood
      vessel function. Participants will then be randomly assigned to receive either pentoxifylline
      or placebo three times a day for 8 weeks. At study visits at Weeks 4 and 8, participants will
      undergo repeat baseline measurements.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Flow-mediated Dilation of the Brachial Artery</measure>
    <time_frame>Measured at baseline and Week 8</time_frame>
    <description>Flow-mediated dilation is nn in vivo measure of arterial endothelial function. We assessed changes in flow-mediated dilation from baseline to week 8.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Soluble TNF-Receptor I Levels</measure>
    <time_frame>Measured at baseline and Week 8</time_frame>
    <description>Measure of systemic inflammation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>HIV</condition>
  <condition>Cardiovascular Diseases</condition>
  <condition>Atherosclerosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive pentoxifylline.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pentoxifylline</intervention_name>
    <description>400 mg three times a day for 8 weeks</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>One pill three times a day for 8 weeks</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Documentation of HIV infection with a positive HIV enzyme-linked immunosorbent assay
             (ELISA) test and confirmatory western blot test

          -  CD4 cell count greater than 350/µL at the time of screening

          -  Has not received any antiretroviral therapies in the 6 months before screening

          -  No anticipated need for any antiretroviral therapies during the course of this study,
             as determined by the principal investigator or by the participant's HIV caregiver

        Note: There is no HIV-1 RNA level eligibility criterion.

        Exclusion Criteria:

          -  Incarceration at the time of screening or at any study visit

          -  Diagnosed vascular disease, including history of angina pectoris, coronary disease,
             peripheral vascular disease, cerebrovascular disease, aortic aneurysm, or otherwise
             known atherosclerotic disease

          -  Diagnosed disease or process, other than HIV infection, associated with increased
             systemic inflammation (including, but not limited to, systemic lupus erythematosis,
             inflammatory bowel diseases, or other collagen vascular diseases). Hepatitis B or C
             co-infections are NOT exclusionary.

          -  History of bleeding diathesis, gastrointestinal ulceration or bleeding,
             cerebrovascular aneurysm or bleeding, or retinal hemorrhage

          -  Known or suspected cancer requiring systemic treatment in the 6 months before
             screening

          -  History of American Diabetes Association (ADA)-defined diabetes mellitus. History of
             gestational diabetes is not exclusionary if the potential participant does not have
             current ADA-defined diabetes.

          -  History of migraine headaches

          -  History of Raynaud's phenomenon

          -  History of cardiac arrhythmias or cardiomyopathy

          -  History of hypothyroidism or hyperthyroidism, even if treated

          -  Known allergy or intolerance to pentoxifylline or other methylxanthines (e.g.,
             theophylline, caffeine, theobromine). Use of caffeinated products, except on the
             mornings of the study visits, is not exclusionary.

          -  Known allergy or intolerance to nitroglycerin

          -  History of carotid bruits

          -  Creatinine clearance less than 50 mL/min, using the Cockcroft-Gault equation and a
             serum creatinine level measured in the 28 days before screening or at the screening
             visit

          -  Hemoglobin less than 9.0 mg/dL in the 28 days before screening or at the screening
             visit

          -  Alanine aminotransferase (ALT) level or aspartate aminotransferase (AST) greater than
             three times the upper limit of normal (ULN) in the 28 days before screening or at the
             screening visit

          -  Total bilirubin greater than 2.5 times the ULN in the 28 days before screening or at
             the screening visit

          -  Fever, defined as a temperature greater than or equal to 38.0 C in the 48 hours before
             screening. Fever in the 48 hours before each study visit will require postponement of
             that study visit until the participant's temperature has been lower than 38.0 C for at
             least 48 hours; fevers continuing past the allowed study visit timeframe will result
             in study discontinuation.

          -  Therapy for acute infection or other serious medical illnesses in the 14 days before
             screening. Therapy for acute infection or other serious medical illnesses that
             overlaps with a study visit will result in postponement of that study visit until the
             course of therapy is completed; postponement outside of the allowed study visit
             timeframe will result in study discontinuation.

          -  Pregnant or breastfeeding

          -  Hypotension, defined as systolic blood pressure less than 90 mm Hg, at time of
             screening. Hypotension noted prior to brachial artery reactivity testing at each study
             visit will result in study visit postponement of at least 1 day until systolic
             pressure is greater than or equal to 90 mm Hg the morning of brachial reactivity
             testing; postponement outside of the allowed study visit timeframe will result in
             study discontinuation.

          -  Hypertension, defined as the receipt of any antihypertensive medication in the 28 days
             before screening or systolic blood pressure greater than 160 mm Hg at the screening
             visit

          -  Receipt of anti-inflammatory agents (including, but not limited to, plaquenil,
             infliximab, etanercept, mycophenolate mofetil, sirolimus, tacrolimus, cyclosporine,
             pentoxifylline, or thalidomide) in the 28 days before screening

          -  Receipt of investigational agents, cytotoxic chemotherapy, systemic or topical
             glucocorticoids (of any dose), or anabolic steroids in the 28 days before screening.
             Physiologic testosterone replacement therapy is not exclusionary.

          -  Receipt of lipid-lowering drugs, aspirin, other non-steroidal anti-inflammatory drugs
             (NSAIDS), acetazolamide, anticoagulants, anticonvulsants, or thyroid replacements in
             the 28 days before screening

          -  Use of sildenafil, vardenafil, or tadalafil in the 72 hours before or after each study
             visit

          -  Active drug or alcohol use or dependence that, in the opinion of the investigator,
             would interfere with adherence to study requirements
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Samir K. Gupta, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Indiana Clinical Research Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 21, 2008</study_first_submitted>
  <study_first_submitted_qc>November 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 24, 2008</study_first_posted>
  <results_first_submitted>March 13, 2013</results_first_submitted>
  <results_first_submitted_qc>March 28, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 17, 2013</results_first_posted>
  <last_update_submitted>October 23, 2017</last_update_submitted>
  <last_update_submitted_qc>October 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Indiana University</investigator_affiliation>
    <investigator_full_name>Samir K Gupta, MD, MS</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Endothelial Function</keyword>
  <keyword>Inflammation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pentoxifylline</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Study recruitment, enrollment, and follow-up assessments were performed from May 2009 through October 2011, at the HIV outpatient clinics of the Indiana University Health medical system.</recruitment_details>
      <pre_assignment_details>Potential participants underwent a screening visit to evaluate eligibility within 21 days of randomization.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Pentoxifylline</title>
          <description>Participants will receive pentoxifylline.
Pentoxifylline : 400 mg three times a day for 8 weeks</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Participants will receive placebo.
Placebo : One pill three times a day for 8 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Pentoxifylline</title>
          <description>Participants will receive pentoxifylline.
Pentoxifylline : 400 mg three times a day for 8 weeks</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Participants will receive placebo.
Placebo : One pill three times a day for 8 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
            <count group_id="B2" value="13"/>
            <count group_id="B3" value="26"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34" spread="10.9"/>
                    <measurement group_id="B2" value="40" spread="11.6"/>
                    <measurement group_id="B3" value="37" spread="11.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Flow-mediated Dilation of the Brachial Artery</title>
        <description>Flow-mediated dilation is nn in vivo measure of arterial endothelial function. We assessed changes in flow-mediated dilation from baseline to week 8.</description>
        <time_frame>Measured at baseline and Week 8</time_frame>
        <population>Number of remaining participants at week 8 with evaluable vascular ultrasonography. In the Pentoxifylline group, 10 participants were evaluated at week 8 but only 9 had evaluable ultrasonography.</population>
        <group_list>
          <group group_id="O1">
            <title>Pentoxifylline</title>
            <description>Participants will receive pentoxifylline.
Pentoxifylline : 400 mg three times a day for 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants will receive placebo.
Placebo : One pill three times a day for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Flow-mediated Dilation of the Brachial Artery</title>
          <description>Flow-mediated dilation is nn in vivo measure of arterial endothelial function. We assessed changes in flow-mediated dilation from baseline to week 8.</description>
          <population>Number of remaining participants at week 8 with evaluable vascular ultrasonography. In the Pentoxifylline group, 10 participants were evaluated at week 8 but only 9 had evaluable ultrasonography.</population>
          <units>absolute percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.93" spread="3.03"/>
                    <measurement group_id="O2" value="-1.06" spread="1.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The sample size was determined based on a two-sample, independent, two-tailed t-test with 5% type I error. Using the results from our pilot trial, we conservatively estimated a predicted absolute change in FMD of 3.5% with PTX (assuming no change with placebo) and we assumed a common standard deviation of 2.6%. A sample size of 10 per group was estimated to provide at least 80% power to detect this effect size. Allowing for a 20% dropout rate, we planned to recruit 13 subjects per group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.44</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.87</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>1.09</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.53</ci_lower_limit>
            <ci_upper_limit>3.28</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Soluble TNF-Receptor I Levels</title>
        <description>Measure of systemic inflammation</description>
        <time_frame>Measured at baseline and Week 8</time_frame>
        <population>Those who had both baseline and Week 8 data available</population>
        <group_list>
          <group group_id="O1">
            <title>Pentoxifylline</title>
            <description>Participants will receive pentoxifylline.
Pentoxifylline : 400 mg three times a day for 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants will receive placebo.
Placebo : One pill three times a day for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Soluble TNF-Receptor I Levels</title>
          <description>Measure of systemic inflammation</description>
          <population>Those who had both baseline and Week 8 data available</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.9" spread="168.97"/>
                    <measurement group_id="O2" value="-83.2" spread="137.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>There was no formal power calculation for this outcome measure as the study was powered on the primary outcome measure.</non_inferiority_desc>
            <p_value>0.03</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>149.1</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>151.8</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>16.4</ci_lower_limit>
            <ci_upper_limit>281.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>8 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Pentoxifylline</title>
          <description>Participants will receive pentoxifylline.
Pentoxifylline : 400 mg three times a day for 8 weeks</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Participants will receive placebo.
Placebo : One pill three times a day for 8 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>All gastrointestinal</sub_title>
                <description>Nausea, vomiting, belching, dyspepsia, diarrhea</description>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="13"/>
                <counts group_id="E2" events="8" subjects_affected="5" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated liver function tests</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Samir K. Gupta</name_or_title>
      <organization>Indiana University School of Medicine</organization>
      <phone>317-274-7926</phone>
      <email>sgupta1@iu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

